These findings demonstrated that combined administration of ACLY inhibitor ETC-1002 and IGF1R inhibitor Linsitinib significantly inhibited HOXA13-mediated CRC metastasis (Fig. 6F). The gene discussed is IGF1R; the disease is colorectal carcinoma.